Skip to main contentAI and Advanced
/
DCAL · NSEMarket ticker unavailable · configure an authorised index feed
DC
NSE · Equity shares · Biotechnology & Drugs-4.35 · -2.62%
Dishman Carbogen Amcis DCAL
NSE:INR 161.65
BSE:INR 194
Data quality and coveragePrice, company fundamentals and optional research feeds are tracked separately.
Headline priceLast market snapshot
Company fundamentalsStale · last-known data
Research sections9 of 9 availableMissing source values remain unavailable, never zero-filled.
Temporary source issue: live-price. Available sections remain usable while the affected layer retries on a later request.
AI analysis and Advanced tools for DCAL
Analysis, reports, chat and Advanced access use the same Rusaka Markets account. The backend remains authoritative for roles, subscriptions, credits and permissions.
Snapshot
Price and key statistics
Reported and computed values remain separate; missing values are not converted to zero.
Previous closeINR 166
Day rangeINR 158.5 — INR 167.99
52-week rangeINR 128.5 — INR 321.95
Volume1.84 L
Market cap3,057.26
P/E20.93
Fundamental highlightsReported values unless marked as computed
Revenue (INR Cr)2,931.9
Net Income (INR Cr)97.45
Rev Growth (5 Year %)8.93
P/E Ratio20.93
Book Value94.32
EPS6.45
Price/BV1.71Computed
Research path: Interpret Dishman Carbogen Amcis's snapshot alongside the wider market dashboard, the financial-statement research guide and the valuation-ratios field guide.
Validated OHLC
Interactive price chart
Crosshair, OHLCV tooltip, indicators, volume, zoom and pan use the same candle API as the advanced workspace.
DCALDishman Carbogen Amcis1d · INR · NSE
Loading validated candles…
Auditable calculations
Daily technical summary
Calculated from validated daily candles. Descriptive research only.
Calculating technicals…
Indicators describe price behaviour and volatility; they are not a BUY, NEUTRAL or SELL recommendation.
Company reporting
Financial statements
IND AS · INR crore
| Metric | 2026 | 2025 | 2024 |
|---|---|---|---|
| Total Liabilities Shareholders' Equity | 11,923.31 | 9,999.15 | 9,581.41 |
| Cash Equivalents | 991.21 | 10 | 2.56 |
| Other Liabilities Total | 1,159.3 | 841.08 | 827.66 |
| Long Term Debt | 1,534.86 | 1,147.02 | 243.23 |
| Common Stock Total | 31.36 | 31.36 | 31.36 |
| Other Current Assets Total | 116.02 | 84.92 | 16.52 |
| Total Assets | 11,923.31 | 9,999.15 | 9,581.41 |
| Current Portof LT Debt/Capital Leases | 1,317.91 | 344.09 | 160.17 |
| Total Equity | 6,676.9 | 5,831.52 | 5,627.5 |
| Long Term Investments | 99.24 | 76.1 | 83.17 |
| Retained Earnings(Accumulated Deficit) | 6,645.54 | 210.14 | 171.32 |
| Total Common Shares Outstanding | 15.68 | 15.68 | 15.68 |
| Tangible Book Valueper Share Common Eq | 94.32 | 94.72 | 95.27 |
| Goodwill Net | 4,798.41 | 4,053.56 | 3,910.68 |
| Total Liabilities | 5,246.41 | 4,167.63 | 3,953.91 |
| Total Debt | 3,076.06 | 2,388.95 | 2,312.6 |
| Short Term Investments | 39.59 | 172.53 | 167.3 |
| Cashand Short Term Investments | 1,030.8 | 458.2 | 431.39 |
| Total Receivables Net | 676.16 | 742.67 | 540.72 |
| Deferred Income Tax | 11.91 | 12.25 | 39.33 |
| Accounts Receivable-Trade Net | 672.91 | 669.81 | 463.26 |
| Property/Plant/Equipment Total-Net | 3,443.22 | 3,171.08 | 3,232 |
| Total Current Liabilities | 2,317.05 | 1,924.79 | 2,554.72 |
| Total Inventory | 1,019.12 | 900.24 | 882.89 |
| Accounts Payable | 211.18 | 230.68 | 244.12 |
| Other Currentliabilities Total | 787.96 | 528.2 | 380.7 |
| Total Long Term Debt | 1,758.15 | 1,389.51 | 532.2 |
| Intangibles Net | 399.68 | 292.92 | 223.14 |
| Other Long Term Assets Total | 208.72 | 40.87 | 33.35 |
| Note Receivable-Long Term | 131.94 | 164.2 | 170.88 |
| Total Current Assets | 2,842.1 | 2,200.42 | 1,928.19 |
| Capital Lease Obligations | 223.29 | 242.49 | 288.97 |
| Accumulated Depreciation Total | Not available | -2,627.34 | -2,731.98 |
| Accrued Expenses | Not available | 166.47 | 149.5 |
| Other Equity Total | Not available | 851.26 | 686.06 |
| Prepaid Expenses | Not available | 14.39 | 56.67 |
| Additional Paid-In Capital | Not available | 4,738.76 | 4,738.76 |
| Cash | Not available | 275.67 | 261.53 |
| Property/Plant/Equipment Total-Gross | Not available | 5,798.42 | 5,463.15 |
| Notes Payable/Short Term Debt | Not available | 655.35 | 1,620.23 |
Fundamentals
Valuation and ratios
Growth
Debt 5Yr CAGR %14.13
Margins
Operating Margin 12m7.61
Operating Margin 5y Avg3.51
Net Profit Margin 12m3.32
Net Profit Margin 5y-0.5
Yield
Dividend Yield %0
Valuation
Price to Sale Ratio1.04
Risk and consensus
Source-qualified signals
Risk metrics
Overall RiskHigh risk
Board Risk57.08
Analyst consensus
Analyst consensus unavailable.
Provider consensus uses a 1 (Strong Buy) to 5 (Strong Sell) score. The payload does not include price targets, so none are inferred from 52-week prices or recommendation percentages.Industry context
Peer comparison
Only peers present in the company profile payload are displayed.
| Company | Price | Market cap | P/E | Research |
|---|---|---|---|---|
| Sun Pharmaceutical Industries | INR 1,944 | 4.66 L | 38.4 | — |
| Divi's Laboratories | INR 8,291.55 | 2.20 L | 73.32 | — |
| Torrent Pharmaceuticals | INR 4,965 | 1.89 L | 72.73 | — |
| Cipla | INR 1,475 | 1.19 L | 27.57 | — |
| Zydus Lifesciences | INR 1,106.25 | 1.10 L | 21.19 | — |
Shareholding
Ownership
- Promoter
- 59.32%
- FII
- 6.86%
- MF
- 1.41%
- Other
- 32.41%
Company intelligence
Latest relevant news
Source, timestamp and external destination are shown. Provider relevance scores are not available.
Dishman Carbogen Amcis Ltd is Rated Strong Sell - Markets MojoMarket news · 4 Jun 2026, 9:40 am
Dishman Carbogen Amcis Ltd is Rated Strong Sell Markets Mojo
Dishman Carbogen Amcis Ltd Technical Momentum Shifts Amid Mixed Market Signals - Markets MojoMarket news · 4 Jun 2026, 8:05 am
Dishman Carbogen Amcis Ltd Technical Momentum Shifts Amid Mixed Market Signals Markets Mojo
Dishman Carbogen Amcis Ltd is Rated Strong Sell - Markets MojoMarket news · 3 Jun 2026, 2:01 am
Dishman Carbogen Amcis Ltd is Rated Strong Sell Markets Mojo
Dishman Carbogen Amcis Ltd Technical Momentum Shifts Amid Mixed Market Signals - Markets MojoMarket news · 2 Jun 2026, 9:18 am
Dishman Carbogen Amcis Ltd Technical Momentum Shifts Amid Mixed Market Signals Markets Mojo
Dishman Carbogen Amcis Ltd Technical Momentum Shifts Amid Mixed Market Signals - Markets MojoMarket news · 31 May 2026, 11:02 am
Dishman Carbogen Amcis Ltd Technical Momentum Shifts Amid Mixed Market Signals Markets Mojo
Dishman EGM set for June 19 to approve ECB - scanx.tradeMarket news · 28 May 2026, 12:30 pm
Dishman EGM set for June 19 to approve ECB scanx.trade
Corporate actions
Events
- annual General MeetingEGM
- board MeetingsAudited Results
- board MeetingsTo consider Fund Raising
- board MeetingsQuarterly Results
- board MeetingsTo consider Fund Raising
- board MeetingsQuarterly Results
- annual General MeetingAGM
- annual General MeetingPOM
Rusaka Markets Community
Discussion and sentiment for Dishman Carbogen Amcis
Posts are linked to the canonical company record. Community BUY, NEUTRAL and SELL opinions are user-generated, moderated and separate from analyst consensus and Rusaka Markets AI.
Checking your Rusaka Markets account…
Company profile
Business information
What the company does
Dishman Carbogen Amcis Limited is engaged in offering contract research and manufacturing services (CRAMS) and the manufacture and supply of marketable molecules such as specialty chemicals, vitamins and chemicals, and disinfectants. Its segments include CRAMS and Marketable Molecules. The CRAMS segment includes Contract Research Services and Contract Manufacturing Services, which it offers to its customers. Through its CRAMS business, the Company assists drug manufacturers in the development and optimization of processes for novel drug molecules in various stages of the development process. The Marketable Molecules segment manufactures and supplies intermediates, quaternary compounds, specialty chemicals, and various products for pharmaceuticals and cosmetics. It has manufacturing and research facilities in India, Switzerland, France, the Netherlands, the United Kingdom, and China. Its subsidiaries include CARBOGEN AMCIS (Shanghai) Co. Ltd, Dishman Infrastructure Ltd., and others.
Company facts
- Industry
- Biotechnology & Drugs
- Sector
- Biotechnology & Drugs
- NSE Code
- DCAL
- BSE Code
- 540701
Questions
Stock FAQ
What is the symbol and ISIN of Dishman Carbogen Amcis?
Dishman Carbogen Amcis has the symbol DCAL and ISIN - INE385W01011.
What is the current price of Dishman Carbogen Amcis?
Dishman Carbogen Amcis is currently trading at INR 161.65.
What are the year high and year low of Dishman Carbogen Amcis?
Dishman Carbogen Amcis has a year high of INR 321.95 and a year low of INR 128.50.
What is the market capitalization of Dishman Carbogen Amcis?
Dishman Carbogen Amcis has a market capitalization of INR 3,057.26 crore.
What is the P/E ratio of Dishman Carbogen Amcis?
Dishman Carbogen Amcis has a P/E ratio of 20.93.
What is the dividend yield of Dishman Carbogen Amcis?
Dishman Carbogen Amcis has a dividend yield of 0.00%.
How is the financial performance of Dishman Carbogen Amcis based on revenue, net income, and EPS?
Dishman Carbogen Amcis has revenue of INR 2,931.90 crore, net income of INR 97.45 crore, and EPS of INR 6.35.
What is the book value of Dishman Carbogen Amcis?
Dishman Carbogen Amcis has a book value of INR 94.32.
What is the debt-to-equity ratio of Dishman Carbogen Amcis?
Dishman Carbogen Amcis has a debt-to-equity ratio of NA.
What are the price-to-book and price-to-sales ratios of Dishman Carbogen Amcis?
Dishman Carbogen Amcis has a price-to-book ratio of 1.71 and a price-to-sales ratio of 1.04.
Corporate-action adjustment is provider-defined. Rusaka Markets research and computed indicators are not investment advice.